Salute e Benessere

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress…

Throughout the congress, participants engaged in in-depth discussions regarding the impact of environmental factors on allergic diseases. Recognizing the growing prevalence of allergies worldwide, sessions examined the influence of climate change, pollution, and urbanization on disease development. These discussions emphasized the need for interdisciplinary approaches to tackle the environmental challenges affecting global health. Throughout the congress, participants engaged in in-depth...
PR Newswire
12/06/2023

Translumina bolsters its German presence with acquisition of Lamed GmbH

Lazaros Ayvatoglou, the founder of Lamed, is convinced to have chosen the right partner in Translumina for further development of its well-established platform. He said, "After the initial discussion, it was clear that both businesses enrich each other with manifold growth opportunities. I am happy to have found a partner that builds on the established foundation of Lamed for a successful future." Lazaros Ayvatoglou, the founder of Lamed, is convinced to have chosen the right partner…
PR Newswire
12/06/2023

Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to…

According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced they have reached a settlement and license agreement with Johnson...
Nasdaq GlobeNewswire
12/06/2023

FDA Clears CorNeat EverPatch, World's First Non-degradable, Synthetic Tissue…

The CorNeat EverPatch is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission. The CorNeat EverPatch is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission. Dr.Gilad Litvin, CorNeat Vision's Chief Medical Officer and Co-Founder stated: "The ideal graft material should be long-lasting, sterile, immunologically...
PR Newswire
12/06/2023

Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in…

Bagsværd , Denmark, 12 June 2023 -Novo Nordisk today announced plans to invest 15.9 billion Danish kroner starting in 2023 1to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases. The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where 21,000-plus employees – approximately half of the company's global workforce 2- still work today. The majority of...
Nasdaq GlobeNewswire
12/06/2023

Mendus presents comprehensive ADVANCE II immunomonitoring data at the EHA Annual…

VIDIDENCEL ADMINISTRATION LED TO BROAD IMMUNE ACTIVATION WITH INNATE AND ADAPTIVE IMMUNE RESPONSES OBSERVED Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, presented new clinical data from the Phase 2 ADVANCE II clinical trial in acute myeloid leukemia (AML) maintenance at the European Hematology Association (EHA) 2023 Hybrid Congress. The data demonstrate that vididencel treatment led to increased levels of...
Nasdaq GlobeNewswire
12/06/2023

Beacon Therapeutics launches with £96 million ($120 million) to develop a new…

PRESS RELEASE Beacon Therapeutics launches with £96 million($120 million)to develop a new generation of gene therapies for retinal diseases resulting in blindnessNew leading gene therapy company created combining late-stage X-linked retinitis pigmentosa (XLRP) program from AGTC, a preclinical program spun out from the University of Oxford and a second preclinical program to deliver a broad ophthalmic development pipelineLed by a h...
Nasdaq GlobeNewswire
12/06/2023

Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal…

Top-line Data Expected in Q4 2023 Leuven, BELGIUM, Boston, MA, US –June 12 , 2023 – 8:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) (KALAHARI trial). Oxurion's...
Nasdaq GlobeNewswire
12/06/2023

Idorsia launches QUVIVIQ (daridorexant) in Switzerland – a first-in-class…

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia, characterized by symptoms present for at least three months and considerable impact on daytime functioningQUVIVIQ, Switzerland's first approved dual orexin receptor antagonist, offers a new targeted mechanism of action that decreases nighttime overactive wakefulness in insomniaAllschwil, Switzerland – June 12 , 2023Idorsia Ltd (SIX: IDIA) today announced that QUVIVIQ™ (daridorexant) is now available to...
Nasdaq GlobeNewswire
12/06/2023

Novartis bolsters innovative medicines strategy and renal pipeline with…

Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney diseaseAgreed deal to include atrasentan, an oral endothelin A receptor antagonist, in Phase 3 development for IgAN, and zigakibart, an anti-APRIL monoclonal antibody, entering Phase 3 for IgANUp to USD 3.5bn transaction (includes USD 40 cash / share plus...
Nasdaq GlobeNewswire
12/06/2023

ERYTECH Responds to Akkadian's Disinformation

ERYTECH Responds to Akkadian's Disinformation Akkadian's challenge of the merger is based on incomplete information and misleading argumentsAkkadian has not presented any valuable alternative optionAkkadian's unfounded actions present a risk of destruction of shareholder value and loss of employment at two companies , and the potential loss of a strategically important technology in FranceIn this context, ERYTECH reminds its...
Nasdaq GlobeNewswire
12/06/2023

SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Poland

“We are very proud that Cosma has chosen SOMAÍ Pharmaceuticals as their preferred manufacturer to penetrate the Polish market with our extract formulations,” said SOMAÍ Pharmaceuticals CEO and Chairman Michael Sassano. “Being one of the first manufacturers in a large market with positive regulatory reforms must have good partners like Cosma that can effectively educate and represent our current and future product offerings.”By the terms of the agreement, SOMAÍ has agreed to supply medical...
Nasdaq GlobeNewswire
12/06/2023

Ipsen to present new data on clinical outcomes and patient validation tools from…

Seven abstracts to be presented demonstrating treatment effects of Bylvay ®in two cholestatic liver diseases, progressive familial intrahepatic cholestasis and Alagille syndrome Data to be presented from a qualitative trial on patient validation of pruritus (itch) and fatigue assessment tools for people living with primary biliary cholangitis (PBC), used as part of the ELATIVE Phase III registrational trial for elafibranorPARIS, FRANCE, 12June 2023– Ipsen (Euronext: IPN;...
Nasdaq GlobeNewswire
12/06/2023

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology…

During the study, patients were assessed in the allergen exposure chamber before commencing AIT and after 12 months of treatment. The chamber provided a controlled environment, allowing patients to be exposed to HDM allergen under stable and well-regulated conditions. Various clinical endpoints, including total nasal symptom score (TNSS), visual analog scale (VAS), and objective parameters such as acoustic rhinometry, peak nasal inspiratory flow (PNIF), and nasal secretion weight, were used to…
PR Newswire
11/06/2023

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology…

In a recent Phase II study, PQ Grass demonstrated a significant dose-response relationship in reducing symptoms, leading to the identification of the optimally effective and safe cumulative dose of 27,600 standardised units (SU). Building on these promising results, an exploratory Phase III trial was conducted to evaluate the combined symptom and medication score (CSMS) of PQ Grass compared to placebo. In a recent Phase II study, PQ Grass demonstrated a significant dose-response relationship…
PR Newswire
11/06/2023

Annual Congress 2023 of the European Academy of Allergy and Clinical Immunology…

Unlike many existing immunotherapies, which belong to the antibody type called IgG, researchers at King's College London and Guy's and St Thomas' have developed an IgE antibody that leverages the patient's own immune system to target cancer in a distinct manner. The team developed a specific IgE antibody for a marker called chondroitin sulfate proteoglycan 4 (CSPG4), found on the surface of human melanoma cells in up to 70% of cases. While current immunotherapies broadly activate the immune…
PR Newswire
11/06/2023

Essity divests Russian operations

In 2022, Essity's net sales in Russia amounted to approximately 2% of the Group's total net sales. The total earnings impact will be reported when the transaction is finalized but is not expected to have a material financial impact. In 2022, Essity's net sales inRussiaamounted to approximately 2% of the Group's total net sales. The total earnings impact will be reported when the transaction is finalized but is not expected to have a material financial impact. CONTACT: For further...
PR Newswire
10/06/2023

FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI®…

The unanimous decision by the panel of independent experts was based on the supplementary Biologics License Application (sBLA) which includes data from Eisai's large global confirmatory Phase 3 clinical Clarity AD trial. The Clarity AD trial met its prespecified primary endpoint, demonstrating a highly statistically significant slowing of cognitive and functional decline (27%, p=0.00005) compared to placebo over 18 months. Highly statistically significant treatment effects were also observed for…
PR Newswire
10/06/2023

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of…

Peripheral and Central Nervous System Drugs Advisory Committee votedbased on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's diseaseThe PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority reviewLEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer's disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June09, 2023...
Nasdaq GlobeNewswire
10/06/2023

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the…

/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) population. “These clinical data are very positive for patients with r/r B-ALL who have failed multiple lines of treatment options including chemotherapy, CD19 directed CAR T-cell therapy and allogeneic stem cell transplant and encourage further enrollment into the BALLI-01 clinical study” said Nicolas Boissel, M.D., Ph.D., Head of Hematology Adolescent and Young Adult Unit at Hôpital Saint-Louis, Paris, France.The poster...
Nasdaq GlobeNewswire
09/06/2023

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composingthe share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal n...
Nasdaq GlobeNewswire
09/06/2023

Immunohistochemistry (IHC) Market worth $4.7 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939 Browse in-depth TOC on "Immunohistochemistry (IHC) Market" 342 - Tables 48 - Figures 352 - Pages Immunohistochemistry (IHC) Market Scope: The Kits product segment accounted for the highest growth rate in the immunohistochemistry market, by product, during the...
PR Newswire
09/06/2023

EssilorLuxottica: Result of the payment of dividends in shares and record of the…

Result of the payment of dividends in shares and record of the corresponding capital increase Charenton-le-Pont, France(June 9, 2023 – 4:30 pm CET)– The Annual General Meeting of EssilorLuxottica has decided to grant to the shareholders the option to receive their dividend in shares. The price for newly issued shares for the payment of the dividend has been set at Euro 160.91 per share. This price corresponds to 90% of the average of the opening prices quoted on Euronext Paris over the...
Nasdaq GlobeNewswire
09/06/2023

Treating COVID with Metformin Reduces Long COVID Rates

"The results of this study are important because Long COVID can have a significant impact on people's lives," said Carolyn Bramante, MD, principal investigator and an assistant professor at the University of Minnesota Medical School. "Metformin is an inexpensive, safe and widely available drug, and its use as a preventive measure could have significant public health implications." "The results of this study are important because Long COVID can have a significant impact…
PR Newswire
09/06/2023
Altri  Comunicati